Table 2.
Score | Study period | ||||
---|---|---|---|---|---|
|
|||||
Baseline | 2 weeks | 4 weeks | 8 weeks | 12 weeks | |
Conjunctival hyperemia | |||||
Treated eyes | 0.26 ± 0.45 | 0.71 ± 0.60 | 0.79 ± 0.54 | 0.88 ± 0.55 | 0.94 ± 0.44 |
Fellow eyes | 0.24 ± 0.43 | 0.11 ± 0.31 | 0.18 ± 0.46 | 0.22 ± 0.49 | 0.25 ± 0.44 |
P-value | 0.5706 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
SPK | |||||
Treated eyes | 0.07 ± 0.17 | 0.09 ± 0.19 | 0.06 ± 0.13 | 0.05 ± 0.11 | 0.11 ± 0.18 |
Fellow eyes | 0.07 ± 0.19 | 0.04 ± 0.16 | 0.02 ± 0.06 | 0.03 ± 0.09 | 0.06 ± 0.13 |
P-value | 1.0000 | 0.2919 | 0.0894 | 0.4664 | 0.1992 |
Notes: Scores are presented as the mean plus or minus the standard deviation; analyzed by Wilcoxon signed-rank test.